Medical News

RSS

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Emergency physician Mary Claire O'Brien, M.D., of Wake Forest University Baptist Medical Center, has done extensive research on the risks and dangers of alcoholic energy drinks (AEDs).

16 Nov 2009

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.

16 Nov 2009

Sinobiopharma's 23 generic drugs on China's National Essential Drugs List

Sinobiopharma, Inc. is pleased to announce that 23 generic drugs for which the Company has production rights are listed in China's National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

16 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

Sunlight Saunas renamed as Sunlighten

After a thorough, long-term strategic brand-building process, Sunlighten(TM) has been chosen as the new name for health & wellness leader Sunlight Saunas(TM). Under the same ownership and with a renewed sense of corporate mission, Sunlighten has plans for a host of cutting-edge wellness products over the coming years, including advances in its line of long-celebrated infrared saunas.

16 Nov 2009

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

WhereToFindCare web site offers tips for evaluating health care facilities and providers

Consumers now have a free, convenient way to gain control over their health care options. Through the use of the national Web site, WhereToFindCare.com, consumers who share their health care experiences will contribute to quality ratings of hospitals, doctors, nursing homes, diagnostic centers and other health care providers.

16 Nov 2009

PanGenex finalizes partnership with BulovaTech Labs

PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., (“LABS”), a wholly-owned subsidiary of Bulova Technologies Group Inc.

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Yongye International, Inc. a leading manufacturer, developer and distributor of Shengmingsu brand plant and animal nutrient products in the People's Republic of China (PRC), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

Publicly available research center for H1N1 influenza pandemic launched

ebrary®, a leading provider of digital content products and technologies, today announced that it has created a publicly available research center featuring a highly interactive, searchable database of documents pertaining to the H1N1 influenza pandemic.

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Flamel Technologies today announced its financial results for the third quarter of 2009.

16 Nov 2009

Bullseye Anatomic Cruciate Reconstruction System released

CONMED Corporation's CONMED Linvatec arthroscopy unit today announced the release of the Bullseye™ Anatomic Cruciate Reconstruction System, a novel guide system for anatomic cruciate ligament (ACL and PCL) reconstructions of the knee.

16 Nov 2009

Medical News

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Myeloma UK launches innovative clinical trial network

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Enrollment complete in Cytori Therapeutics' international breast cancer reconstruction study

Sinobiopharma's 23 generic drugs on China's National Essential Drugs List

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Sunlight Saunas renamed as Sunlighten

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

WhereToFindCare web site offers tips for evaluating health care facilities and providers

PanGenex finalizes partnership with BulovaTech Labs

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Genta announces Phase 3 trial results of Genasense

Publicly available research center for H1N1 influenza pandemic launched

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Bullseye Anatomic Cruciate Reconstruction System released

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News